These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15145966)

  • 21. Anidulafungin (Eraxis) for Candida infections.
    Med Lett Drugs Ther; 2006 May; 48(1235):43-4. PubMed ID: 16770294
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
    J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.
    Krause DS; Reinhardt J; Vazquez JA; Reboli A; Goldstein BP; Wible M; Henkel T;
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2021-4. PubMed ID: 15155194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
    Dowell JA; Stogniew M; Krause D; Henkel T; Damle B
    J Clin Pharmacol; 2007 Mar; 47(3):305-14. PubMed ID: 17322142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
    Kuti EL; Kuti JL
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1287-300. PubMed ID: 20822479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Echinocandins in invasive candidiasis].
    Glöckner A; Cornely OA
    Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anidulafungin in the treatment of patients with invasive candidiasis.
    Kett DH; Cubillos GF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02.
    Drugs R D; 2003; 4(3):167-73. PubMed ID: 12757403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
    Gumbo T
    Curr Opin Infect Dis; 2007 Dec; 20(6):587-91. PubMed ID: 17975408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients.
    Aoyama T; Hirata K; Hirata R; Yamazaki H; Yamamoto Y; Hayashi H; Matsumoto Y
    J Clin Pharm Ther; 2012 Jun; 37(3):356-63. PubMed ID: 21883330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micafungin: a new echinocandin antifungal.
    Joseph JM; Jain R; Danziger LH
    Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.
    Liu P
    Antimicrob Agents Chemother; 2013 Jan; 57(1):466-74. PubMed ID: 23129052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis.
    Tabata K; Katashima M; Kawamura A; Kagayama A; Kohno S
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):123-8. PubMed ID: 16898081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
    Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
    Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.
    Vazquez JA; Schranz JA; Clark K; Goldstein BP; Reboli A; Fichtenbaum C
    J Acquir Immune Defic Syndr; 2008 Jul; 48(3):304-9. PubMed ID: 18545153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on echinocandin antifungals.
    Kauffman CA; Carver PL
    Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.
    Liu P; Ruhnke M; Meersseman W; Paiva JA; Kantecki M; Damle B
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1672-6. PubMed ID: 23335738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.
    Tabata K; Katashima M; Kawamura A; Kaibara A; Tanigawara Y
    Drug Metab Pharmacokinet; 2006 Aug; 21(4):324-31. PubMed ID: 16946560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.